In a multicenter, retrospective study, DNA methylation signature was identified to be correlated with improved progression-free survival and overall survival (OS) in patients with stage IV non-small cell lung cancer (NSCLC) treated with anti-programmed death-1 (PD-1) agents [13]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.